Dorixina Relax, containing lysine cloxinate, functions as a non-steroidal anti-inflammatory (NSAI) medication primarily targeting pain relief. Its mechanism involves the inhibition of prostaglandin synthesis, particularly targeting the enzyme responsible for producing prostaglandins associated with inflammation (COX-2). Notably, it exhibits lesser activity on the kidneys (COX-1), where prostaglandins play a protective role.
The cyclobenzaprine component alleviates localized skeletal muscle spasms without disrupting muscle function. It effectively reduces muscle spasm and diminishes somatic motor activity, influencing both the gamma and alpha motor systems at the central nervous system level.
Pharmacokinetics
Lysine cloxinate is rapidly absorbed, reaching peak plasma levels approximately 40-60 minutes after administration. Its bioavailability is around 56%, although there may be some individual variability. In humans, the plasma half-life of lysine cloxinate is approximately 1.75±0.10 hours (mean ± SD). Metabolites of lysine cloxinate are mainly excreted in urine, accounting for about 60% of elimination, while its concentration in milk is around 7-10% of plasma levels.
Cyclobenzaprine is readily absorbed and highly bound to plasma proteins once in circulation. Primarily metabolized in the liver, it is predominantly excreted through the kidneys. Its elimination is relatively slow, with an effective half-life ranging from 1 to 3 days.
Indications
Dorixina Relax is recommended for the management of musculoskeletal pain, particularly when accompanied by muscle spasms.
Read Also: Addressing 6 Common Misconceptions About Medical Marijuana Safety
Contraindications
Dorixina Relax should not be used in individuals with known hypersensitivity to Lysine clonixinate or Cyclobenzaprine, active peptic ulcer or gastroduodenal hemorrhage, pregnancy, or in children and adolescents under 15 years of age. It is also contraindicated in patients with a history of bronchospasms, nasal polyps, angioedema, or urticaria caused by the administration of acetylsalicylic acid (aspirin) or other NSAIDs.
Due to the Cyclobenzaprine component, Dorixina Relax is contraindicated during coadministration with monoamine oxidase inhibitors (MAOIs) or within 2 weeks after their discontinuation. Additionally, it should be avoided in individuals with recent acute myocardial infarction, heart failure, arrhythmia, heart block, conduction disturbances, or hyperthyroidism.
Pros and Cons of dorixina
Pros of Dorixina Relax:
- Effective Pain Relief
- Dual Mechanism of Action
- Rapid Absorption
Cons of Dorixina Relax:
- Potential Adverse Effects
- Contraindications and Precautions
- Interaction Risks
Differences Between dorixina and flanax
Dorixina:
Works by inhibiting prostaglandin synthesis, which reduces pain and inflammation. Cyclobenzaprine, the muscle relaxant component, acts centrally on the nervous system to alleviate muscle spasms.
Flanax:
Naproxen sodium also inhibits prostaglandin synthesis, providing pain relief and reducing inflammation.
Alternative to dorixina
Muscle Relaxants:
Alternative muscle relaxants to cyclobenzaprine in Dorixina include methocarbamol, tizanidine, baclofen, and metaxalone. These medications work by relaxing muscles and reducing muscle spasms.
Precautions
If allergic skin and/or mucosal reactions or symptoms of peptic ulcer or gastrointestinal hemorrhage occur, discontinue treatment with Dorixina Relax. The Cyclobenzaprine component may amplify the depressant effects of alcohol, barbiturates, or other CNS depressants. Caution is advised when administering to patients with a history of digestive diseases such as gastroduodenal peptic ulcer or gastritis and in patients treated with anticoagulants.
Although no cases have been reported with the administration of Lysine Clonixinate, NSAIDs inhibit the synthesis of prostaglandins, which play a supportive role in maintaining renal perfusion. In patients with impaired renal blood flow, NSAID administration may precipitate renal decompensation, usually reversible upon discontinuation of the product. Patients at greatest risk include those who are dehydrated, have congestive heart failure, hepatic cirrhosis, nephrotic syndrome, or other renal diseases, as well as those taking diuretics or who have undergone major surgeries resulting in hypovolemia. In such patients, diuresis volume and renal function should be monitored before initiating therapy. While not commonly observed during treatment with Lysine clonixinate, NSAID administration may increase transaminase plasma levels or other liver parameters, though in most cases, these elevations are small and transient.
Cyclobenzaprine, chemically related to tricyclic antidepressants and parasympatholytic drugs, should be used cautiously in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure (IOP), and in those taking anticholinergic medication.
Pediatric use of Cyclobenzaprine is contraindicated as no clinical studies are available for children and adolescents under 15 years of age.
In geriatric patients, like with other anti-inflammatories, Dorixina Relax should be administered with caution due to potential impairment of cardiac, hepatic, or renal functions.
Drug interactions
Other NSAIDs, including high doses of acetylsalicylic acid, increase the risk of gastroduodenal ulcers and hemorrhages due to their synergistic action.
Oral anticoagulants, ticlopidine, heparin (systemic administration), and thrombolytics pose a major risk of hemorrhages when used concurrently with Dorixina Relax. If simultaneous administration is unavoidable, strict monitoring of blood coagulation is necessary, with adjustments made to the dosage of medications affecting coagulation parameters accordingly.
Lithium levels are typically increased by NSAIDs, so close monitoring of lithium plasma levels is necessary when starting, modifying, or discontinuing treatment with Dorixina Relax.
Concomitant use of methotrexate and NSAIDs may heighten the hematological toxicity of methotrexate. In such cases, rigorous hematological monitoring is essential.
In patients receiving diuretics, the potential risk of acute renal failure is elevated with NSAID treatment, particularly in cases of dehydration. If Lysine clonixinate and diuretics are coadministered, patients must be adequately hydrated and their renal function monitored before initiating treatment.
During concomitant therapy with antihypertensive agents and NSAIDs, a decrease in antihypertensive effect has been reported due to the inhibition of vasodilating prostaglandins.
The Cyclobenzaprine component may trigger hyperpyretic crises and convulsions with a fatal outcome when interacting with MAO inhibitors. Additionally, when coadministered with guanethidine and similar compounds, it may theoretically block their antihypertensive action.
Side effects
At therapeutic doses, Dorixina Relax is generally well tolerated. However, in rare cases, especially in sensitive individuals, it may lead to nausea, vomiting, gastritis, and somnolence.
The combination with Cyclobenzaprine may result in somnolence, dry mouth, and dizziness.
Less frequently, occurring in 1-3% of cases, adverse effects may include asthenia, constipation, dyspepsia, unpleasant taste, blurred vision, headache, and nervousness.
Adverse events reported with an incidence of less than 1% include malaise; tachycardia, arrhythmia, hypotension, palpitation; anorexia, vomiting, diarrhea, abdominal pain, gastritis, thirst, flatulence, and abnormal liver function.
On very rare occasions, occurrences such as hepatitis and cholestasis; anaphylaxis, angioedema, pruritus, facial edema or edema of the tongue, urticaria, rash; ataxia, vertigo, dysarthria, tremor, hypertonia, muscle spasms, convulsions, disorientation, insomnia, depressed mood, anxiety, agitation, abnormal thinking and dreaming, excitement, paresthesia, diplopia; sweating; ageusia, tinnitus, and urinary frequency or retention have been reported.
Conclusion
Dorixina Relax is a medication generally well-tolerated at therapeutic doses, although rare adverse effects may occur, particularly in sensitive individuals. Its combination with Cyclobenzaprine can lead to additional side effects such as somnolence, dry mouth, and dizziness. While most adverse reactions are minor and resolve spontaneously, healthcare providers should be vigilant for more serious reactions, albeit rare. As with any medication, the benefits of Dorixina Relax should be weighed against the potential risks, and patients should be monitored closely for any signs of adverse effects during treatment.